• FirefoxInstall the new Firefox »
  •  Dow Down0.45% Nasdaq Down0.49%

    GlycoMimetics, Inc. (GLYC)

    8.32 Up 0.09(1.09%) Feb 27, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    GlycoMimetics, Inc.
    401 Professional Drive
    Suite 250
    Gaithersburg, MD 20879
    United States - Map
    Phone: 240-243-1201
    Fax: 240-243-1018
    Website: http://www.glycomimetics.com

    Index Membership:N/A
    Full Time Employees:27

    Business Summary 

    GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company develops lead product GMI-1070, a glycomimetic drug candidate that has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. It also develops GMI-1271, a specific E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers; and GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Gaithersburg, Maryland.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on GlycoMimetics, Inc.

    Key Executives 
    Mrs. Rachel K. King , 56
    Founder, Chief Exec. Officer and Director
    Mr. Brian M. Hahn , 41
    Chief Financial Officer
    Dr. John L. Magnani Ph.D., 62
    Chief Scientific Officer, VP and Director
    Dr. Helen M. Thackray M.D., FAAP, 47
    Chief Medical Officer and VP of Clinical Devel.
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders